Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Firefly Neuroscience (NASDAQ: AIFF) reported a 373% year-over-year increase in commercial Evoke scan utilization among patients under age 18. The FDA-510(k)-cleared platform assesses brain function, and the reported growth covers patients exhibiting symptoms of ADHD, attention or focus deficits.
Building on its September 2026 commercial agreement with NeuroSigma, Firefly is using its nationwide clinician network to distribute the Monarch eTNS System, an FDA-cleared, non-drug prescription treatment for pediatric ADHD. The company aims to connect diagnostic assessments with treatment in a diagnostic-to-treatment revenue model. Firefly also has a proprietary repository of over 200,000 standardized EEG/ERP brain scans, which it believes strengthens its artificial intelligence models.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointEvoke commercial scan utilization among patients under 18 with ADHD, attention or focus symptoms increased 373% year over year.
- Moderate point. Forward-looking: it has not happened yet and may not happen.September 2026 NeuroSigma agreement supports Monarch eTNS distribution through Firefly’s clinician network toward a planned diagnostic-to-treatment revenue model.
- Minor pointFirefly believes its repository of over 200,000 standardized EEG/ERP brain scans strengthens its artificial intelligence models.
Negative
- None.
Key Figures
- U18 ADHD scan volume growth
- 373% year over year
- Commercial utilization of the Evoke platform
- Proprietary scan dataset
- Over 200,000 standardized EEG/ERP brain scans
- Firefly's proprietary data repository
Historical Context
-
Firefly agreed to introduce Monarch to Evoke clinicians, with NeuroSigma handling training and fulfillment.
-
Evoke scan volumes at TMS-center customers rose 291% year over year.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
510(k) regulatory
eeg medical
erp medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
4.7x expansion in scan volume bodes well for Firefly’s recent commercial partnership to cross-sell non-drug treatment for pediatric ADHD across its growing nationwide network of Evoke™ clinical customers
KENMORE, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ: AIFF), an artificial intelligence ("AI") company advancing precision neuroscience and non-invasive brain-computer interface (BCI) technology, today announced a
This accelerated commercial utilization highlights expanding clinical adoption and revenue-generating scale across Firefly's neurodiagnostic platform, which converts complex electrophysiological data into objective brain-function assessments:
•
• 200,000+ Proprietary Scan Dataset: Every scan expands Firefly’s proprietary data repository of over 200,000 standardized EEG/ERP brain scans, which the Company believes strengthens its AI foundation models and long-term competitive moat.
• Commercial Cross-Sell Synergies: Building on its September 2026 commercial agreement with NeuroSigma, Firefly is actively leveraging its nationwide clinician network to distribute the Monarch eTNS® System — the first FDA-cleared, non-drug prescription treatment for pediatric ADHD — with the goal of creating an end-to-end diagnostic-to-treatment revenue model.
"The
About Firefly Neuroscience
Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence ("AI") company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. Firefly's proprietary database consists of over 200,000 EEG/ERP brain scans, which the Company believes to be the world's largest known standardized EEG/ERP repository. Firefly's EEG-based, AI-driven, and FDA-510(k)-cleared Evoke™ System is designed to support diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and PTSD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" for purposes of the federal securities laws concerning Firefly, including statements relating to Firefly's management team's expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly's control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Firefly Neuroscience’s pediatric Evoke scan utilization grow?
Commercial Evoke scan utilization increased 373% year over year among patients under age 18 exhibiting symptoms of ADHD, attention or focus deficits. Firefly also described the increase as a 4.7-fold gain.